Literature DB >> 22488922

Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy.

Luke A Massey1, Caroline Micallef, Dominic C Paviour, Sean S O'Sullivan, Helen Ling, David R Williams, Constantinos Kallis, Janice L Holton, Tamas Revesz, David J Burn, Tarek Yousry, Andrew J Lees, Nick C Fox, Hans R Jäger.   

Abstract

Conventional magnetic resonance imaging (cMRI) is often used to aid the diagnosis of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), but its ability to predict the histopathological diagnosis has not been systematically studied. cMRI from 48 neuropathologically confirmed cases, including PSP (n = 22), MSA (n = 13), Parkinson's disease (PD) (n = 7), and corticobasal degeneration (n = 6), and controls (n = 9) were assessed blinded to clinical details and systematically rated for reported abnormalities. Clinical diagnosis and macroscopic postmortem findings were retrospectively assessed. Radiological assessment of MRI was correct in 16 of 22 (72.7%) PSP cases and 10 of 13 (76.9%) MSA cases with substantial interrater agreement (Cohen's kappa 0.708; P < .001); no PSP case was misclassified as MSA or vice versa. MRI was less sensitive but more specific than clinical diagnosis in PSP and both more sensitive and specific than clinical diagnosis in MSA. The "hummingbird" and "morning glory" signs were highly specific for PSP, and "the middle cerebellar peduncle sign" and "hot cross bun" for MSA, but sensitivity was lower (up to 68.4%) and characteristic findings may not be present even at autopsy. cMRI, clinical diagnosis, and macroscopic examination at postmortem have similar sensitivity and specificity in predicting a neuropathological diagnosis. We have validated specific radiological signs in pathologically confirmed PSP and MSA. However, the low sensitivity of these and macroscopic findings at autopsy suggest a need for imaging techniques sensitive to microstructural abnormalities without regional atrophy.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Year:  2012        PMID: 22488922     DOI: 10.1002/mds.24968

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  67 in total

Review 1.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

Review 2.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

3.  Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.

Authors:  Sarah Coakeley; Sang Soo Cho; Yuko Koshimori; Pablo Rusjan; Madeleine Harris; Christine Ghadery; Jinhee Kim; Anthony E Lang; Alan Wilson; Sylvain Houle; Antonio P Strafella
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-22       Impact factor: 6.200

Review 4.  Beyond the midbrain atrophy: wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy.

Authors:  Keita Sakurai; Aya M Tokumaru; Keigo Shimoji; Shigeo Murayama; Kazutomi Kanemaru; Satoru Morimoto; Ikuko Aiba; Motoo Nakagawa; Yoshiyuki Ozawa; Masashi Shimohira; Noriyuki Matsukawa; Yoshio Hashizume; Yuta Shibamoto
Journal:  Neuroradiology       Date:  2017-04-06       Impact factor: 2.804

Review 5.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Authors:  Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

6.  Progressive supranuclear palsy and idiopathic Parkinson's disease are associated with local reduction of in vivo brain viscoelasticity.

Authors:  Axel Lipp; Cornelia Skowronek; Andreas Fehlner; Kaspar-Josche Streitberger; Jürgen Braun; Ingolf Sack
Journal:  Eur Radiol       Date:  2018-02-19       Impact factor: 5.315

Review 7.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

Review 8.  Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.

Authors:  Toshihide Ogawa; Shinya Fujii; Keita Kuya; Shin-Ichiro Kitao; Yuki Shinohara; Mana Ishibashi; Yoshio Tanabe
Journal:  Yonago Acta Med       Date:  2018-09-26       Impact factor: 1.641

9.  The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy.

Authors:  Luke A Massey; Hans R Jäger; Dominic C Paviour; Sean S O'Sullivan; Helen Ling; David R Williams; Constantinos Kallis; Janice Holton; Tamas Revesz; David J Burn; Tarek Yousry; Andrew J Lees; Nick C Fox; Caroline Micallef
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

Review 10.  The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes.

Authors:  Florian Holtbernd; David Eidelberg
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.